Kamada (KMDA) FY Conference Summary Company Overview - Kamada is a publicly traded biopharmaceutical company with a commercial stage and six FDA approved products [2][3] - The company has experienced significant growth, with a revenue guidance of $178 million to $182 million for the year, and an EBITDA guidance of $40 million to $44 million [3][10] Financial Performance - Revenue has shown double-digit growth since 2021, starting from approximately $100 million to a projected $180 million this year [10] - EBITDA has increased from $6 million to over $40 million, with a growth rate from 6%-7% to around 24%-25% [10] - The company reported an 11% growth in revenue, 58% growth in earnings per share, and 35% growth in adjusted EBITDA compared to the previous year [11] Growth Strategy - Kamada's growth strategy is based on four pillars: organic growth, M&A, in-licensing of additional products, and opening plasma collection centers [4][12] - The company has opened two plasma collection centers in Houston and San Antonio, with a capacity of around 50,000 donations annually, expected to generate $8 million to $10 million in additional revenue [14][15] - The company is optimistic about potential M&A opportunities that could positively impact profitability by 2026 [13] Product Portfolio - Kamada focuses on specialty plasma-derived products, including alpha-one antitrypsin and five specialty immunoglobulins [5][6] - Key products include: - **Kedra**: An anti-rabies immunoglobulin product, with a market share of approximately 50% and a partnership with Kedrion [16][18] - **CytoGam**: An anti-CMV immunoglobulin used in organ transplantation, with ongoing data collection to support its use [19][39] Market Dynamics - The market for alpha-one deficiency is estimated at $1.3 billion to $1.4 billion, with potential growth to $1.8 billion to $2 billion by 2029 [29][31] - The company is developing a nebulized AAT product to improve treatment efficiency, with a Phase III pivotal study currently underway [27][28] Competitive Landscape - Kamada has carved out a niche in the specialty plasma space, as larger companies have exited due to the market size being too small for them [44][45] - The company does not foresee new plasma companies entering the market due to high entry barriers and complex supply chains [49] - Competition exists from non-plasma products, such as recombinant AAT and gene therapy treatments [50] Future Outlook - Kamada plans to continue expanding its product offerings and market presence, with a focus on partnerships for commercial capabilities in the alpha-one space [41][42] - The company aims to maintain its position as a leading global specialty plasma company, leveraging its unique expertise and capabilities [51]

Financial Data and Key Metrics Changes - Total revenues for the first half of 2025 were $88.8 million, representing an 11% year-over-year increase, while adjusted EBITDA was $22.5 million, up 35% year-over-year, with a 25% margin on revenues [4][11] - For the second quarter, revenues were $44.8 million, up 5% compared to the prior year quarter, and adjusted EBITDA was $10.9 million, up 20% year-over-year [4][11] - Net income for the first half of 2025 was $11.3 million or $0.19 per diluted share, compared to $6.8 million or $0.12 per diluted share in 2024 [13][14] Business Line Data and Key Metrics Changes - Revenue growth for the first half of 2025 was primarily driven by increased sales of Glacier in ex-U.S. markets and VariSig sales in the U.S., as well as Glacier royalty payments [6][7] - The company anticipates launching two additional biosimilars later this year, with expected revenues of approximately $2.5 million in 2025 from the first biosimilar launched in Israel [7][8] Market Data and Key Metrics Changes - The company is ramping up plasma collection at its Texas-based plasma centers, with each center expected to generate annual revenues of between $8 million to $10 million at full capacity [9] - The market for inhaled alpha-one antitrypsin therapy is projected to grow significantly, with expectations that it could reach a $2 billion market by the time the company has results from its study [26] Company Strategy and Development Direction - The company is guided by a four-pillar growth strategy focusing on organic commercial growth, business development and M&A transactions, plasma collection operations, and the advancement of its pivotal Phase III Inhaled AAT program [5][41] - The company is actively conducting due diligence on several potential commercial targets to enrich its portfolio and expects to secure compelling in-licensing collaborations or M&A transactions [8][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing to generate profitable growth through the remainder of 2025 and has increased its adjusted EBITDA guidance to between $40 million to $44 million [5][14] - The company is closely monitoring the evolving tariff situation, assessing that recently imposed tariffs are not applicable to drug products and have not impacted operations [15] Other Important Information - The company ended the first half of 2025 with a cash balance of $66 million, which is planned to be used for new business development initiatives [14] - Gross profit for the first half of 2025 was $39.7 million with a gross margin of 45%, compared to $35.7 million and 45% in 2024 [12] Q&A Session Summary Question: Dynamics behind KEDRAB and Cytogam - Management indicated that KEDRAB and Cytogam are performing according to expectations, with growth anticipated once additional clinical data is available [17][19] Question: Cash position for impactful business development - Management plans to utilize existing cash and has additional funding sources available for commercial stage assets, focusing on plasma-derived products and specialty pharma [22][23] Question: Competitive landscape for inhaled AAT program - Management noted that their inhaled AAT program is the most advanced in terms of efficacy studies, with a growing market and multiple new technologies being developed [24][26] Question: Distribution revenue segment and future outlook - Management confirmed that the revenue from the new biosimilar product is not a one-time sale and expects continued growth in the distribution channel [30][31] Question: SG&A expenses and future expectations - Management stated that they have been disciplined in managing expenses and anticipate a slight fluctuation in the second half of the year but aim to maintain profitability [33][34] Question: Tax rate expectations - Management expects an effective tax rate between 20% and 25% as the company utilizes its tax loss carryforwards [35][38]